These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 32638462)

  • 41. Community-based HPV self-collection versus visual inspection with acetic acid in Uganda: a cost-effectiveness analysis of the ASPIRE trial.
    Mezei AK; Pedersen HN; Sy S; Regan C; Mitchell-Foster SM; Byamugisha J; Sekikubo M; Armstrong H; Rawat A; Singer J; Ogilvie GS; Kim JJ; Campos NG
    BMJ Open; 2018 Jun; 8(6):e020484. PubMed ID: 29895648
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Screening for cervical cancer in India: How much will it cost? A trial based analysis of the cost per case detected.
    Legood R; Gray AM; Mahé C; Wolstenholme J; Jayant K; Nene BM; Shastri SS; Malvi SG; Muwonge R; Budukh AM; Sankaranarayanan R
    Int J Cancer; 2005 Dec; 117(6):981-7. PubMed ID: 16003735
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Cost-effectiveness of cervical cancer screening with primary HPV testing for unvaccinated women in Sweden.
    Fogelberg S; Clements MS; Pedersen K; Sy S; Sparén P; Kim JJ; Burger EA
    PLoS One; 2020; 15(9):e0239611. PubMed ID: 32997696
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Modelling the cost-effectiveness and capacity impact of changes to colposcopy referral guidelines for women with mild dyskaryosis in the UK Cervical Screening Programme.
    Hadwin R; Eggington S; Brennan A; Walker P; Patnick J; Pilgrim H
    BJOG; 2008 May; 115(6):749-57. PubMed ID: 18410660
    [TBL] [Abstract][Full Text] [Related]  

  • 45. HPV-based cervical screening: Rationale, expectations and future perspectives of the new Dutch screening programme.
    Polman NJ; Snijders PJF; Kenter GG; Berkhof J; Meijer CJLM
    Prev Med; 2019 Feb; 119():108-117. PubMed ID: 30594536
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Cost-effectiveness of Leveraging Social Determinants of Health to Improve Breast, Cervical, and Colorectal Cancer Screening: A Systematic Review.
    Mohan G; Chattopadhyay S
    JAMA Oncol; 2020 Sep; 6(9):1434-1444. PubMed ID: 32556187
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Cost-effectiveness of approaches to cervical cancer screening in Malawi: comparison of frequencies, lesion treatment techniques, and risk-stratified approaches.
    Rasmussen PW; Hoffman RM; Phiri S; Makwaya A; Kominski GF; Bastani R; Moses A; Moucheraud C
    BMC Health Serv Res; 2024 Jul; 24(1):792. PubMed ID: 38982430
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Using Decision-Analytic Modeling to Isolate Interventions That Are Feasible, Efficient and Optimal: An Application from the Norwegian Cervical Cancer Screening Program.
    Pedersen K; Sørbye SW; Burger EA; Lönnberg S; Kristiansen IS
    Value Health; 2015 Dec; 18(8):1088-97. PubMed ID: 26686795
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Acceptability of risk-based triage in cervical cancer screening: A focus group study.
    Bas S; Sijben J; Bischoff EWMA; Bekkers RLM; de Kok IMCM; Melchers WJG; Siebers AG; van der Waal D; Broeders MJM
    PLoS One; 2023; 18(8):e0289647. PubMed ID: 37585441
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Moving towards an organized cervical cancer screening: costs and impact.
    Diaz M; Moriña D; Rodríguez-Salés V; Ibáñez R; Espinás JA; de Sanjosé S
    Eur J Public Health; 2018 Dec; 28(6):1132-1138. PubMed ID: 29684144
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Options for managing low grade cervical abnormalities detected at screening: cost effectiveness study.
    TOMBOLA Group
    BMJ; 2009 Jul; 339():b2549. PubMed ID: 19638648
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Systematic review of model-based cervical screening evaluations.
    Mendes D; Bains I; Vanni T; Jit M
    BMC Cancer; 2015 May; 15():334. PubMed ID: 25924871
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Disability-Adjusted Life Years Averted Versus Quality-Adjusted Life Years Gained: A Model Analysis for Breast Cancer Screening.
    Davidović M; Zielonke N; Lansdorp-Vogelaar I; Segnan N; de Koning HJ; Heijnsdijk EA
    Value Health; 2021 Mar; 24(3):353-360. PubMed ID: 33641769
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Epidemiologic and Health Economic Evaluation of Cervical Cancer Screening in Rural China.
    Zhao F; Wen Y; Li Y; Tao S; Ma L; Zhao Y; Dang L; Wang Y; Zhao F; Lang J; Qiao Y; Yang CX
    Asian Pac J Cancer Prev; 2020 May; 21(5):1317-1325. PubMed ID: 32458639
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Which screening strategy should be offered to women with BRCA1 or BRCA2 mutations? A simulation of comparative cost-effectiveness.
    de Bock GH; Vermeulen KM; Jansen L; Oosterwijk JC; Siesling S; Dorrius MD; Feenstra T; Houssami N; Greuter MJ
    Br J Cancer; 2013 Apr; 108(8):1579-86. PubMed ID: 23579217
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Cost-Effectiveness Analysis of HPV Extended versus Partial Genotyping for Cervical Cancer Screening in Singapore.
    Chua B; Lim LM; Ng JSY; Ma Y; Wee HL; Caro JJ
    Cancers (Basel); 2023 Mar; 15(6):. PubMed ID: 36980698
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Modeling the Balance of Benefits and Harms of Cervical Cancer Screening with Cytology and Human Papillomavirus Testing.
    Malagón T; Mayrand MH; Ogilvie G; Gotlieb WH; Blake J; Bouchard C; Franco EL; Kulasingam S
    Cancer Epidemiol Biomarkers Prev; 2020 Jul; 29(7):1436-1446. PubMed ID: 32332032
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Cost of the Cervical Cancer Screening Program at the Mexican Social Security Institute.
    Granados-García V; Flores YN; Pérez R; Rudolph SE; Lazcano-Ponce E; Salmerón J
    Salud Publica Mex; 2014; 56(5):502-10. PubMed ID: 25604295
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Finding the optimal mammography screening strategy: A cost-effectiveness analysis of 920 modelled strategies.
    Kregting LM; Sankatsing VDV; Heijnsdijk EAM; de Koning HJ; van Ravesteyn NT
    Int J Cancer; 2022 Jul; 151(2):287-296. PubMed ID: 35285018
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Economic evaluation of three populational screening strategies for cervical cancer in the county of Valles Occidental: CRICERVA clinical trial.
    Acera A; Rodriguez A; Trapero-Bertran M; Soteras P; Sanchez N; Bonet JM; Manresa JM; Hidalgo P; Toran P; Prieto G
    BMC Health Serv Res; 2011 Oct; 11():278. PubMed ID: 22011387
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.